Cyclooxygenases and colon cancer

Prostaglandins and Other Lipid Mediators

Volumn 68-69, Issue , 2002, Pages 187-196

  Kawai, Naoki ^a   Tsujii, Masahiko ^a   Tsuji, Shingo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colon cancer; COX 2

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; UVOMORULIN; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INTERACTION; COLON CARCINOGENESIS; COLON CARCINOMA; HUMAN; INTESTINE EPITHELIUM; INTESTINE POLYP; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CELL ADHESION; CELL CYCLE; COLON TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REVIEW; STROMA CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL ADHESION; CELL CYCLE; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STROMAL CELLS;

EID: 0036669841     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(02)00030-8     Document Type: Article

References (45)

1. Giovannucci E., Egan K.M., Hunter D.J.et al. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333:1995;609-614.
2. Giardiello F.M., Hamilton S.R., Krush A.J.et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328:1993;1313-1316.
3. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthetase 2. Cell. 83:1995;493-501.
4. Dewitt D.L. Mol. Pharmacol. 55:1999;625-631.
5. Sano H., Kawahito Y., Wilder R.L.et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789.
6. DuBois R.N., Radhika A., Reddy B.S.et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology. 110:1996;1259-1262.
7. Williams C.S., Luongo C., Radhika A.et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 111:1996;1134-1140.
8. Shattuck-Brandt R.L., Varilek G.W., Radhika A.et al. Cyclooxygenase-2 expression is increased in the stroma of colon carcinomas from IL-10 (-/-) mice. Gastroenterology. 118:2000;337-345.
9. Sinicrope F.A., Lemoine M., Xie L.et al. Reduced expression of cyclooxygenase-2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology. 117:1999;350-358.
10. Pugh S., Thomas G.A.O. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut. 35:1994;675-678.
11. Oshima M., Dinchuk J.E., Kargman S.L.et al. Suppression of intestinal polyposis in Apc (delta 716) knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell. 87:1996;803-809.
12. Singer I.I., Kawka D.W., Schloemann S.et al. Cyclooxygenase-2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology. 115:1998;297-306.
13. McCartney S.A., Mitchell J.A., Fairclough P.D.et al. Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment. Pharmacol. Ther. 13:1999;1115-1117.
14. Agoff S.N., Brentnall T.A., Crispin D.A.et al. The role of cyclooxygenase-2 in ulcerative colitis-associated neoplasia. Am. J. Pathol. 157:2000;737-745.
15. Muller-Decker K., Albert C., Lukanov T.et al. Cellular localization of cyclooxygenase isozymes in Crohn's disease and colorectal cancer. Int. J. Colorectal. Dis. 14:1999;212-218.
16. Bamba H., Ota S., Kato A.et al. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer. 83:1999;470-475.
17. Di Popolo A., Memoli A., Apicella A.et al. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene. 19:2000;5517-5524.
18. Vadlamudi R., Mandal M., Adam L.et al. Regulation of cyclooxygenase-2 pathway by HER-2 receptor. Oncogene. 18:1999;305-314.
19. Hull M.A., Booth J.K., Tisbury A.et al. Cyclooxygenase-2 is up-regulated and localized to macrophages in the intestine of Min mice. Br. J. Cancer. 79:1999;1399-3405.
20. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69:2000;145-182.
21. Sonoshita M., Takaku K., Sasaki N.et al. Acceleration of intestinal polyposis through prostaglandin receptor EP-2 in Apc (delta 716) knockout mice. Nat. Med. 7:2001;1048-1051.
22. DuBois R.N., Shao J., Tsujii M.et al. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 56:1996;733-737.
23. Sheng H., Shao J., Kirkland S.C.et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 99:1997;2254-2259.
24. Sheng H., Shao J., Morrow J.D.et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58:1998;362-366.
25. Piazza G.A., Rahm A.K., Finn T.S.et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57:1997;2452-2459.
26. Shiff S.J., Qiao L., Tsai L.L.et al. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Invest. 96:1995;491-503.
27. Boolbol S.K., Dannenberg A.J., Chadburn A.et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 56:1996;2556-2560.
28. Williams C.S., Watson A.J., Sheng H.et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60:2000;6045-6051.
29. Grosch S., Tegeder I., Niederberger E.et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 15:2001;2742-2744.
30. Carroll K.M., Wong T.T., Drabik D.L.et al. Differentiation of rat small intestinal epithelial cells by extracellular matrix. Am. J. Physiol. 254:1988;G355-G360.
31. Williams C.S., Tsujii M., Reese J.et al. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105:2000;1589-1594.
32. Narko K., Ristimaki A., MacPhee M. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J. Biol. Chem. 272:1997;21455-21460.
33. Jones M.K., Wang H., Peskar B.M.et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5:1999;1418-1423.
34. Tsujii M., Kawano S., Tsuji S.et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
35. Dormond O., Foletti A., Paroz C.et al. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading migration and angiogenesis. Nat. Med. 7:2001;1041-1047.
36. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3336-3340.
37. Fujita T., Matsui M., Takaku K.et al. Size- and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res. 58:1998;4823-4826.
38. Hardwick J.C., van den Brink G.R., Offerhaus G.J.et al. NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene. 20:2001;819-827.
39. Tsuji S., Tsujii M., Kawano S., Hori M. COX-2 up-regulation as a periepigenetic change carcinogenesis. J. Exp. Clin. Cancer. Res. 20:2001;117-129.
40. Tegeder I., Pfeilschifter J., Geisslinger G.et al. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15:2001;2057-2072.
41. Hanif R., Pittas A., Feng Y.et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 52:1996;237-245.
42. Chiu C.H., McEntee M.F., Whelan J. Sulindac causes rapid regression of pre-existing tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res. 57:1997;4267-4273.
43. Zhang X., Morham S.G., Langenbach R.et al. Malignant transformation and anti-neoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190:1999;451-459.
44. Gupta R.A., DuBois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. 1:2001;11-21.
45. Oshima M., Murai N., Kargman S.et al. Chemoprevention of intestinal polyposis in the Apc delta 716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61:2001;1733-1740.